- Home
- SRFM vs VOR Comparison
SRFM vs VOR Comparison
Compare SRFM & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- VOR
- Stock Information
- Founded
- SRFM 2011
- VOR 2015
- Country
- SRFM United States
- VOR United States
- Employees
- SRFM N/A
- VOR N/A
- Industry
- SRFM Transportation Services
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- VOR Health Care
- Exchange
- SRFM Nasdaq
- VOR Nasdaq
- Market Cap
- SRFM 62.8M
- VOR 57.1M
- IPO Year
- SRFM 2023
- VOR 2021
- Fundamental
- Price
- SRFM $5.61
- VOR $1.27
- Analyst Decision
- SRFM Hold
- VOR Strong Buy
- Analyst Count
- SRFM 2
- VOR 7
- Target Price
- SRFM $3.40
- VOR $11.36
- AVG Volume (30 Days)
- SRFM 762.4K
- VOR 855.3K
- Earning Date
- SRFM 11-14-2024
- VOR 11-07-2024
- Dividend Yield
- SRFM N/A
- VOR N/A
- EPS Growth
- SRFM N/A
- VOR N/A
- EPS
- SRFM N/A
- VOR N/A
- Revenue
- SRFM $118,212,000.00
- VOR N/A
- Revenue This Year
- SRFM $102.41
- VOR N/A
- Revenue Next Year
- SRFM $47.46
- VOR N/A
- P/E Ratio
- SRFM N/A
- VOR N/A
- Revenue Growth
- SRFM 198.78
- VOR N/A
- 52 Week Low
- SRFM $0.90
- VOR $0.63
- 52 Week High
- SRFM $11.48
- VOR $3.14
- Technical
- Relative Strength Index (RSI)
- SRFM 69.40
- VOR 72.30
- Support Level
- SRFM $2.64
- VOR $0.82
- Resistance Level
- SRFM $3.67
- VOR $0.89
- Average True Range (ATR)
- SRFM 0.82
- VOR 0.11
- MACD
- SRFM 0.12
- VOR 0.01
- Stochastic Oscillator
- SRFM 78.87
- VOR 100.00
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.